Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management

touchEXPERT OPINIONS for touchONCOLOGY

Listen to three leading experts sharing their perspectives on the impact of the 2022 guideline updates on diagnosis, classification and management of higher-risk myelodysplastic neoplasms (MDS) and acute myeloid leukaemia (AML).

 The experts:

• Prof. Andrew Wei, Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
• Prof. Agnieszka Wierzbowska, Medical University of Lodz, Poland
• Prof. Gert Ossenkoppele, Vrije Universiteit University Medical Center, Amsterdam, Netherlands

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Novartis and is provided by touchIME. 

For further information visit: www.touchoncology.com/education/impact-of-new-guidelines-in-MDS-AML